Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Meiji Yasuda Asset Management Co Ltd.

Meiji Yasuda Asset Management Co Ltd. trimmed its position in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 9.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,823 shares of the medical research company’s stock after selling 1,000 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Edwards Lifesciences were worth $812,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of EW. Bogart Wealth LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $25,000. MV Capital Management Inc. lifted its holdings in shares of Edwards Lifesciences by 74.1% in the 3rd quarter. MV Capital Management Inc. now owns 329 shares of the medical research company’s stock worth $27,000 after acquiring an additional 140 shares during the last quarter. Wagner Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $44,000. New Millennium Group LLC acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $54,000. Finally, Boit C F David acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $54,000. 80.35% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Daveen Chopra sold 4,000 shares of the stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $74.80, for a total transaction of $299,200.00. Following the completion of the sale, the vice president now owns 18,911 shares in the company, valued at approximately $1,414,542.80. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the firm’s stock in a transaction on Monday, January 9th. The shares were sold at an average price of $77.50, for a total value of $521,187.50. Following the completion of the sale, the vice president now owns 62,561 shares in the company, valued at approximately $4,848,477.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daveen Chopra sold 4,000 shares of the firm’s stock in a transaction on Thursday, December 15th. The stock was sold at an average price of $74.80, for a total transaction of $299,200.00. Following the completion of the sale, the vice president now owns 18,911 shares of the company’s stock, valued at approximately $1,414,542.80. The disclosure for this sale can be found here. Insiders sold a total of 101,386 shares of company stock worth $7,858,324 in the last 90 days. Company insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $68.00 to $76.00 and gave the stock a “hold” rating in a report on Wednesday, February 1st. Royal Bank of Canada cut their target price on shares of Edwards Lifesciences from $118.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, November 28th. Canaccord Genuity Group cut their target price on shares of Edwards Lifesciences from $78.00 to $73.00 and set a “hold” rating on the stock in a research note on Monday, December 12th. Wells Fargo & Company downgraded shares of Edwards Lifesciences from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $97.00 to $78.00 in a research note on Wednesday, March 8th. Finally, Citigroup cut their target price on shares of Edwards Lifesciences from $99.00 to $92.00 and set a “buy” rating on the stock in a research note on Monday, December 12th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $88.95.

Edwards Lifesciences Trading Up 2.1 %

Shares of Edwards Lifesciences stock opened at $78.20 on Wednesday. The company has a fifty day simple moving average of $78.08 and a 200-day simple moving average of $79.52. Edwards Lifesciences Co. has a 12-month low of $67.13 and a 12-month high of $131.10. The company has a current ratio of 3.03, a quick ratio of 2.17 and a debt-to-equity ratio of 0.10. The stock has a market cap of $47.57 billion, a price-to-earnings ratio of 32.05, a PEG ratio of 4.33 and a beta of 1.01.

Edwards Lifesciences (NYSE:EW – Get Rating) last issued its earnings results on Tuesday, January 31st. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.03. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.33 billion. Edwards Lifesciences had a net margin of 28.27% and a return on equity of 26.05%. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.51 EPS. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.52 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.